Dosage and time schedule of pegIFN-α2a* treatment for HCV genotype 1b infected chimeric mice
| Dose | |||||||
|---|---|---|---|---|---|---|---|
| Donor hepatocytes† | No of chimeric mice | Inoculum | Test compound | Level (μg/kg) | Concentrtion (μg/ml) | Volume (ml/kg) | Frequency |
| A | 3 | Serum A | Peg-IFN-α2a | 30 | 3 | 10 | Day 0, 3, 7, 10 |
| B | 4 | Serum A | Peg-IFN-α2a | 30 | 3 | 10 | Day 0, 3, 7, 10 |
| C | 3 | Serum A | Peg-IFN-α2a | 30 | 3 | 10 | Day 0, 3, 7, 10 |
| D | 3 | Serum A | Peg-IFN-α2a | 30 | 3 | 10 | Day 0, 3, 7, 10 |
| A | 2 | Serum B | Peg-IFN-α2a | 30 | 3 | 10 | Day 0, 3, 7, 10 |
| C | 2 | Serum B | Peg-IFN-α2a | 30 | 3 | 10 | Day 0, 3, 7, 10 |
| A | 2 | Serum C | Peg-IFN-α2a | 30 | 3 | 10 | Day 0, 3, 7, 10 |
| C | 2 | Serum C | Peg-IFN-α2a | 30 | 3 | 10 | Day 0, 3, 7, 10 |
*Pegasys; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
†The IL28B genetic variation of the donor hepatocytes was indicated in table 2.
HCV, hepatitis C virus; peg-IFN-α, pegylated interferon α.